"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves obinutuzumab for Previously Untreated Follicular Lymphoma

28 Nov 2017 9:43 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to obinutuzumab (Gazyva; Genentech) in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II buly; III, or IV follicular lymphoma (FL). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software